

LACRYSTIM™

TREATMENT OF

DRY EYE



IPL System



THE BENEFITS OF


DIAGNOSIS LACRYDIAG

Eye surface analyser



TREATMENT LACRYSTIM

IPL System



ADDED VALUE FOR YOUR CLINICAL PRACTICE

- Extend your clinical offering from diagnosis to treatment.
- Diagnose and treat the cause of dry eye earlier.
- Understand the origin of dry eye to offer a more targeted and effective treatment.
- Assess post-treatment results.
- Improve the compliance of patients under topical treatment for glaucoma.



IMPROVE YOUR PATIENT'S UNDERSTANDING OF DRY EYE

- Perform a complete, fast contactless examination.
- Offer your patients painless and effective IPL treatment (< 5 min).
- Provide evidence for diagnosis and treatment
- Provides patient care.
- Satisfy your patients, customised post treatment analysis.

LACRYSTIM™

Dry eye is a particularly common disease that affects the **health and well-being** of millions of people worldwide. **Meibomian gland dysfunction** (MGD) is the leading cause of dry eye syndrome, known as evaporative dry eye, because it causes excessive tear evaporation.


The **IPL LacryStim system** (Intense Pulsed Light) helps stimulate and reactivate the meibomian glands in order to treat dry eye.¹⁻⁶ Intense Pulsed Light technology is one of a series of innovative technologies **acknowledged in the DEWS II Report**.

TREATS THE CAUSES OF DRY EYE OPTIMISING LONG-TERMS RESULTS.

■ MECHANISMS OF ACTION

Several studies detail the mechanisms of action of IPL systems:

- **Neurostimulation of the parasympathetic nerve pathways:**¹⁻²
Tear production is stimulated by the nervous system, via the parasympathetic nerve³, which is linked to both the lacrimal gland³⁻⁴ and the meibomian glands^{3,5}.
- **Faster meibomian gland metabolism:**¹⁻⁵
- **Increased meibum expression due to heat**⁶
- Small vessel coagulation: **acts against inflammation of the skin** (rosacea) and **eyelids** (blepharitis)⁷⁻⁹
- **Reduces Demodex mites.**



■ CLINICAL RESULTS

The expected results of IPL treatment may include⁶:

- Improved **tear film quality**.
- Patient-reported **improvement in the following symptoms:** dryness, sensation of foreign body in the eye, itching, burning, eye fatigue, blurred vision, sensitivity to light, watery eyes, impaired secretion, pain.
- **Additional effects of IPL treatment may be observed:**
 - Pain relief
 - Anti-inflammatory action (blepharitis, conjunctivitis, rosacea)
 - Reduction in inflammatory markers (cytokines) in the tears¹⁰
 - Antimicrobial action (bacteria and Demodex mites).

IPL System


LIGHT SPECTRUM

- An IPL device is a generator of **polychromatic intense pulsed light**.
- The LacyStim light spectrum extends **from 610 nm to 1200 nm**.
- LacyStim uses a **610 nm filter** that blocks UVA, UVB and UVC rays.
- Thanks to **this 610 nm filter**:
 - The **melanin** in the skin **absorbs less light** [11]
 - **No phototyping** is required
 - **All types of skin** can be treated, including black skin (Fitzpatrick scale phototype VI).



SETTINGS AND PULSE SEQUENCE

- **The total energy** is between 8 and 12 J/cm² and is delivered in a **sequence of pulses**.
- The **time between each pulse respects the thermal relaxation time (TRT) of the skin**, thus limiting:
 - The increase in tissue temperature
 - Thermal damage to the skin
 - Inflammatory reactions
 - The phototyping required.



EFFECTIVE TREATMENT FOR ALL SKIN TYPES




■ A COMPACT AND ERGONOMIC SYSTEM

- A single handpiece, no additional kit required.
- Integrated water cooling.
- Does not burn the skin.
- Applies a thin layer of gel during treatment.
- Long-lasting flash lamp.
- Delivers the same energy level from first to last shot.



■ SIMPLE AND FAST TREATMENT



LACRYSTIM™

TECHNICAL SPECIFICATIONS



LACRYSTIM™	
Technology	IPL (Intense Pulsed Light)
Wavelength	610 – 1200 nm
Energy	1 to 14 J/cm ²
Dimensions	580 (H) x 275 (W) x 280 (D) mm
Weight	25 kg
Filter	610 nm, anti UVA, UVB and UVC filter
Cooling system	Water Replace water every 7000 shots
Flash lamp	Xenon lamp
Power supply	230 VAC or 110 VAC
Temperature for use	+5°C to +35°C
Treatment duration	3 to 4 sessions
Accessories	Operator safety glasses, patient eyeshields
CE marking	Class IIb medical device

The company reserves the right to modify the technical specifications without prior warning.
© 2019. Quantel Medical, LacyStim is a registered trademark of Quantel Medical. All rights reserved.

BIBLIOGRAPHY

1. Parasympathetic Innervation of the Meibomian Glands in Rats - Mark, S. LeDoux, Qihong Zhou, R. Bryan Murphy, Melissa, L. Greene y Patrick Ryan - *Investigative Ophthalmology & Visual Science*, octubre de 2001, Vol. 42, No. 11
2. Neurotransmitter Influence on Human Meibomian Gland Epithelial Cells. - Wendy R. Kam y David A. Sullivan - *Investigative Ophthalmology & Visual Science*, noviembre de 2011, vol. 52, No. 12
3. TFOS DEWS II - Rapport Physiopathologie, Anthony J. Bron, FRCOph, FMedSci, Cintia S. de Paiva, MD, PhD1, Sunil K. Chauhan, DVM, PhD1, Stefano Bonini, MD, Eric E. Gabison, MD, Sandeep Jain, MD, Erich Knop, MD, PhD, Maria Markoulli, PhD, MOptom, Yoko Ogawa, MD, Victor Pérez, MD, Yuichi Uchino, MD, PhD, Norihiko Yokoi, MD, PhD, Driss Zoukhri, PhD, David A. Sullivan, PhD, *The Ocular Surface*, 2017, pp. 441-515
4. Vasoactive Intestinal Polypeptide and the Innervation of the Human Lacrimal Gland, Patrick A. Sibony, MD; Benjamin Walcott, PhD; Cissy McKeon, Frederick A. Jakobiec, MD, *Arch Ophthalmol*. 1988;106(8), pp. 1085-1088
5. The neurobiology of the meibomian glands, Cox SM, Nichols JJ, *Ocular Surface*, julio de 2014
6. Arita R. et al. Multicenter Study of Intense Pulsed Light Therapy for Patients With Refractory Meibomian Gland Dysfunction - Reiko Arita, MD, PhD, Takanori Mizoguchi, MD, Shima Fukuoka, MD, and Naoyuki Morishige, MD, PhD - *Cornea*, volumen 37, número 12, diciembre de 2018
7. Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition, Yu Ri Woo, Ji Hong Lim, Dae Ho Cho and Hyun Jeong Park, *International Journal of Molecular Sciences*, septiembre de 2016
8. Rosacea: Epidemiology, pathogenesis, and treatment, Barbara M. Rainer, Sewon Kang, and Anna L. Chien, *DERMATO-ENDOCRINOLOGY* 2018, VOL. 9, NO. 1, e1361574 (10 páginas)
9. Update on the management of rosacea, Allison P Weinkle, Vladyslava Doktor, Jason Emer, *Clinical, Cosmetic and Investigational Dermatology*, abril de 2015
10. Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction - RUIXING LIU, BEI RONG, PING TU, YUN TANG, WENJING SONG, ROLANDO TOYOS, MELISSA TOYOS Y XIAOMING YAN - *Am J Ophthalmol*. 2017 en AJO.com.
11. Theory of lasers and lamps - S. Mordon, T. Michaud - *Annales de dermatologie* (2009) 136, suplemento 6, S3066s310 - www.sciencedirect.com